ABSTRACT
OBJECTIVE: To evaluate adherence to guidelines when choosing an empirical treatment and its impact upon the prognosis of community-acquired pneumonia (CAP). METHODS: A prospective multicentre study was conducted in 425 CAP patients hospitalized on ward. Initial empirical treatment was classified as adhering or not to Spanish guidelines. Adherent treatment was defined as an initial antimicrobial regimen consisting of beta-lactams plus macrolides, beta-lactam monotherapy and quinolones. Non-adherent treatments included macrolide monotherapy and other regimens. Initial severity was graded according to pneumonia severity index (PSI). The end point variables were mortality, length of stay (LOS) and re-admission at 30 days. RESULTS: Overall 30-day mortality was 8.2%, the mean LOS was 8+/-5 days, and the global re-admission rate was 7.6%. Adherence to guidelines was 76.5%, and in most cases the empirical treatment consisted of beta-lactam and macrolide in combination (57.4%). Logistic regression analysis showed that other regimens were associated with higher mortality OR=3 (1.2-7.3), after adjusting for PSI and admitting hospital. Beta-lactam monotherapy was an independent risk factor for re-admission. LOS was independently associated with admitting hospital and not with antibiotics. CONCLUSIONS: A high adherence to CAP treatment guidelines was found, though with considerable variability in the empirical antibiotic treatment among hospitals. Non-adherent other regimens were associated with greater mortality. Beta-lactam monotherapy was associated with an increased re-admission rate.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Pneumonia, Bacterial/drug therapy , Practice Guidelines as Topic , Aged , Aged, 80 and over , Community-Acquired Infections/drug therapy , Epidemiologic Methods , Female , Guideline Adherence/statistics & numerical data , Humans , Length of Stay/statistics & numerical data , Macrolides/therapeutic use , Male , Middle Aged , Patient Readmission/statistics & numerical data , Prognosis , Quinolones/therapeutic use , Severity of Illness Index , Spain , Treatment Outcome , beta-Lactams/therapeutic useSubject(s)
Bronchoscopy/adverse effects , Ecchymosis/etiology , Thrombocytopenia/complications , Face , Female , Fiber Optic Technology , Humans , Middle AgedABSTRACT
Stevens-Johnson syndrome is characterized by generalized exanthema associated with high fever, catarrhal symptoms and mucositis. Various etiologies have been implicated, particularly numerous medications and certain agents of atypical pneumonia. Stevens-Johnson syndrome leads to death in up to 5% of cases. We describe the case of a 30-year-old woman with bilateral atypical pneumonia accompanied by severe generalized exanthema that required hospitalization in the serious burns unit of our hospital. She was diagnosed with Stevens-Johnson syndrome following atypical pneumonia caused by Mycoplasma pneumoniae with microbiological and pathological confirmation.
Subject(s)
Pneumonia, Mycoplasma/complications , Stevens-Johnson Syndrome/etiology , Adult , Anti-Bacterial Agents , Combined Modality Therapy , Diarrhea/etiology , Drug Therapy, Combination/therapeutic use , Female , Fluid Therapy , Humans , Mycoplasma pneumoniae , Oxygen Inhalation Therapy , Pneumonia, Mycoplasma/microbiology , Pneumonia, Mycoplasma/therapy , Respiratory System Agents/therapeutic use , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/therapyABSTRACT
El síndrome de Stevens-Johnson se caracteriza por un exantema generalizado asociado a fiebre alta, síntomas catarrales y mucositis. Ha sido relacionado con varias etiologías, entre las que destacan numerosos fármacos y algunos agentes productores de neumonías atípicas, y puede llegar a ser mortal hasta en el 5 por ciento de las ocasiones. Presentamos el caso de una paciente joven con una neumonía atípica bilateral que se acompañó de un exantema generalizado muy importante y requirió ingreso en la Unidad de Grandes Quemados de nuestro hospital. Fue diagnosticada de síndrome de Stevens-Johnson tras neumonía atípica por Mycoplasma pneumoniae con confirmación microbiológica y anatomopatológica (AU)
